Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Classical hematology 1

Conditions

Leukemia 25Leukemia, Myeloid, Acute 23Myelodysplastic Syndromes 22Lymphoma 18Leukemia, Lymphocytic, Chronic, B-Cell 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Lymphoma, Non-Hodgkin 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Hodgkin Disease 15Multiple Myeloma 11Hematologic Neoplasms 11Primary Myelofibrosis 9Myeloproliferative Disorders 9Lymphoma, Mantle-Cell 8Lymphoma, Large B-Cell, Diffuse 8Graft vs Host Disease 8Lymphoma, Follicular 7Lymphoma, B-Cell, Marginal Zone 7Lymphoma, Large-Cell, Immunoblastic 6Leukemia, Myelomonocytic, Juvenile 6Leukemia, Myelomonocytic, Chronic 6Burkitt Lymphoma 6Leukemia, Myeloid, Accelerated Phase 5Waldenstrom Macroglobulinemia 4Neoplasms 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Extranodal NK-T-Cell 4Leukemia, Neutrophilic, Chronic 4Leukemia, Myeloid, Chronic-Phase 4Congenital Abnormalities 4

Interventions

Imatinib Mesylate 6Cytarabine 5ponatinib 4nilotinib 4venetoclax 3fludarabine phosphate 3Mycophenolic Acid 3thymoglobulin 2fludarabine 2enasidenib 2Methotrexate 2Lenalidomide 2Cyclosporine 2Cyclophosphamide 2Azacitidine 2Antilymphocyte Serum 2quizartinib 1methanesulfonic acid 1glasdegib 1etoposide phosphate 1daratumumab 1bosutinib 1asciminib 1Whole-Body Irradiation 1Transplantation 1Temozolomide 1Tacrolimus 1Stem Cell Transplantation 1Standard of Care 1RFT5-SMPT-dgA immunotoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Leukemia, Myeloid × thymoglobulin × Clear all
NCT00568633 2019-09-24

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Stanford University

Phase 3 Terminated
58 enrolled 18 charts
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT01392989 2019-05-07

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

Stanford University

Phase 2 Completed
44 enrolled 13 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neural Tube Defects

Data powered by HemOnc (CC BY 4.0) Colophon âš¡